{"id":803937,"date":"2025-01-23T09:08:49","date_gmt":"2025-01-23T14:08:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/"},"modified":"2025-01-23T09:08:49","modified_gmt":"2025-01-23T14:08:49","slug":"abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/","title":{"rendered":"AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>\n          <i>Collaboration leverages\u00a0AbbVie&#8217;s expertise in oncology and immunology drug development and Neomorph&#8217;s leading molecular glue discovery platform<\/i>\n        <\/li>\n<li>\n          <i>Neomorph to receive an upfront payment and is eligible to receive future option fees and milestones of up to <span class=\"xn-money\">$1.64B<\/span><\/i>\n        <\/li>\n<\/ul>\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NORTH CHICAGO, Ill.<\/span> and <span class=\"xn-location\">SAN DIEGO<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Jan. 23, 2025<\/span><\/span> \/PRNewswire\/ &#8212; AbbVie (NYSE: ABBV) and Neomorph, Inc.\u00a0today announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology.<\/p>\n<p>Molecular glue degraders are a novel class of small molecules that are designed to selectively target and trigger degradation of proteins that drive cancer growth or immune system dysregulation, offering a more precise approach to treatment. Molecular glue degraders have the potential to target proteins that have historically been defined as &#8220;undruggable&#8221;.<\/p>\n<p>&#8220;Protein degraders represent a groundbreaking advancement in the field of drug discovery and at AbbVie we are committed to advancing this technology forward,&#8221; said <span class=\"xn-person\">Steven Elmore<\/span>, vice president, small molecule therapeutics and platform technologies at AbbVie. &#8220;We are excited to collaborate with Neomorph to develop novel molecular glue degraders which could pave the way for new, effective therapies in the treatment of immune disorders and cancer.&#8221;<\/p>\n<p>&#8220;At Neomorph, we have spent years building a unique molecular glue platform with broad coverage of the proteome,&#8221; said <span class=\"xn-person\">Phil Chamberlain<\/span>, DPhil, Co-Founder, President, and Chief Executive Officer of Neomorph. &#8220;We are thrilled to partner with AbbVie, a global leader in delivering transformative medicines in oncology and immunology, as we aim to tackle some of the most challenging and valuable targets known.&#8221;<\/p>\n<p>Under terms of the agreement, Neomorph will receive an upfront payment from AbbVie, and is eligible to receive up to <span class=\"xn-money\">$1.64 billion<\/span> in aggregate option fees and milestones, as well as tiered royalties on net sales.<\/p>\n<p>\n        <b>About AbbVie <br \/><\/b>AbbVie&#8217;s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. AbbVie strives to have a remarkable impact on people&#8217;s lives across several key therapeutic areas \u2013 immunology, oncology, neuroscience, and eye care \u2013 and products and services in AbbVie&#8217;s Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4346011-1&amp;h=1581576442&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4324514-1%26h%3D4253239866%26u%3Dhttp%253A%252F%252Fwww.abbvie.com%252F%26a%3Dwww.abbvie.com&amp;a=www.abbvie.com\" target=\"_blank\" rel=\"nofollow\">www.abbvie.com<\/a>. Follow @abbvie on\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4346011-1&amp;h=3004979061&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4324514-1%26h%3D2517638250%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Fabbvie%252F%26a%3DLinkedIn%252C&amp;a=LinkedIn%2C\" target=\"_blank\" rel=\"nofollow\">LinkedIn,<\/a>\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4346011-1&amp;h=3807726356&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4324514-1%26h%3D4147250696%26u%3Dhttps%253A%252F%252Fwww.facebook.com%252FAbbVieGlobal%252F%26a%3DFacebook&amp;a=Facebook\" target=\"_blank\" rel=\"nofollow\">Facebook<\/a>,\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4346011-1&amp;h=1880457953&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4324514-1%26h%3D2870297646%26u%3Dhttps%253A%252F%252Fwww.instagram.com%252Fabbvie%252F%26a%3DInstagram&amp;a=Instagram\" target=\"_blank\" rel=\"nofollow\">Instagram<\/a>,\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4346011-1&amp;h=260836196&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4324514-1%26h%3D3555355528%26u%3Dhttps%253A%252F%252Ftwitter.com%252Fabbvie%26a%3DX%2B(formerly%2BTwitter)&amp;a=X+(formerly+Twitter)\" target=\"_blank\" rel=\"nofollow\">X (formerly Twitter)<\/a>, and\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4346011-1&amp;h=1066252482&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4324514-1%26h%3D1170106983%26u%3Dhttps%253A%252F%252Fwww.youtube.com%252Fuser%252FAbbVie%26a%3DYouTube.&amp;a=YouTube.\" target=\"_blank\" rel=\"nofollow\">YouTube.<\/a>\u00a0<\/p>\n<p>\n        <b>About Neomorph<br \/><\/b>Neomorph is a biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against &#8216;undruggable&#8217; targets. Neomorph was founded in 2020 and is venture-backed by Deerfield Management Company.<\/p>\n<p>Neomorph&#8217;s team is comprised of industry-leading experts in protein degradation and molecular glues who have a track record of groundbreaking discoveries in the field. The team at Neomorph is committed to leadership in advancing the science and technology of molecular glue drug discovery, while prosecuting a pipeline of projects through clinical development.<\/p>\n<p>Neomorph is headquartered in <span class=\"xn-location\">San Diego, California<\/span>. For more information, visit\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4346011-1&amp;h=2064011705&amp;u=http%3A%2F%2Fwww.neomorph.com%2F&amp;a=www.neomorph.com\" target=\"_blank\" rel=\"nofollow\">www.neomorph.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4346011-1&amp;h=2307701973&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fneomorph-llc%2Fmycompany%2F&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1755\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/386913\/AbbVie_logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/386913\/AbbVie_logo.jpg\" title=\"AbbVie logo\" alt=\"AbbVie logo\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG02030&amp;sd=2025-01-23\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology-302357741.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology-302357741.html<\/a><\/p>\n<p>SOURCE  AbbVie<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CG02030&amp;Transmission_Id=202501230900PR_NEWS_USPR_____CG02030&amp;DateId=20250123\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Collaboration leverages\u00a0AbbVie&#8217;s expertise in oncology and immunology drug development and Neomorph&#8217;s leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible to receive future option fees and milestones of up to $1.64B NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 \/PRNewswire\/ &#8212; AbbVie (NYSE: ABBV) and Neomorph, Inc.\u00a0today announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology. Molecular glue degraders are a novel class of small molecules that are designed to selectively target and trigger degradation of proteins that drive cancer growth or immune system dysregulation, offering a more precise approach to treatment. Molecular glue degraders have the potential to target proteins that &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-803937","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Collaboration leverages\u00a0AbbVie&#8217;s expertise in oncology and immunology drug development and Neomorph&#8217;s leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible to receive future option fees and milestones of up to $1.64B NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 \/PRNewswire\/ &#8212; AbbVie (NYSE: ABBV) and Neomorph, Inc.\u00a0today announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology. Molecular glue degraders are a novel class of small molecules that are designed to selectively target and trigger degradation of proteins that drive cancer growth or immune system dysregulation, offering a more precise approach to treatment. Molecular glue degraders have the potential to target proteins that &hellip; Continue reading &quot;AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-23T14:08:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/386913\/AbbVie_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology\",\"datePublished\":\"2025-01-23T14:08:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\\\/\"},\"wordCount\":510,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/386913\\\/AbbVie_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\\\/\",\"name\":\"AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/386913\\\/AbbVie_logo.jpg\",\"datePublished\":\"2025-01-23T14:08:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/386913\\\/AbbVie_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/386913\\\/AbbVie_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/","og_locale":"en_US","og_type":"article","og_title":"AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology - Market Newsdesk","og_description":"PR Newswire Collaboration leverages\u00a0AbbVie&#8217;s expertise in oncology and immunology drug development and Neomorph&#8217;s leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible to receive future option fees and milestones of up to $1.64B NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 \/PRNewswire\/ &#8212; AbbVie (NYSE: ABBV) and Neomorph, Inc.\u00a0today announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology. Molecular glue degraders are a novel class of small molecules that are designed to selectively target and trigger degradation of proteins that drive cancer growth or immune system dysregulation, offering a more precise approach to treatment. Molecular glue degraders have the potential to target proteins that &hellip; Continue reading \"AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-23T14:08:49+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/386913\/AbbVie_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology","datePublished":"2025-01-23T14:08:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/"},"wordCount":510,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/386913\/AbbVie_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/","name":"AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/386913\/AbbVie_logo.jpg","datePublished":"2025-01-23T14:08:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/386913\/AbbVie_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/386913\/AbbVie_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/803937","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=803937"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/803937\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=803937"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=803937"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=803937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}